Compare NEOS S&P 500 High Income ETF (SPYI) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs TG Therapeutics Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: NEOS S&P 500 High Income ETF is the larger of the two by market cap, and NEOS S&P 500 High Income ETF is more actively traded (3,058,962 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold NEOS S&P 500 High Income ETF for 58 Days and TG Therapeutics Inc for 16 Days on average.
| SPYI | TGTX | |
|---|---|---|
Market Cap | $12.50B | $8.16B |
Volume | 3,058,962 | 1,735,121 |
Sector | Income / Options Overlay | Health |
52-Week High | $54.42 | $59.06 |
52-Week Low | $47.98 | $26.94 |
Typical Hold Time | 58 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI trades at $54.09 with a slight 0.15% daily gain, showing modest upward momentum amid bullish technical signals. The ETF maintains a strong income focus with recent monthly dividends around $0.53-0.54, though key valuation metrics remain unavailable. Technical analysis indicates bullish moving averages but neutral oscillators, with RSI-6 suggesting potential overbought conditions at 72.22.
SPYI offers high-income generation through covered call strategies but faces principal erosion risks as highlighted in recent analysis. The ETF's 12% yield attracts retirement investors, though coverage warns of potential capital depletion with systematic withdrawals. Market sentiment remains mixed between income appeal and long-term growth concerns.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
